Description: Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.

Description: Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.

Description: These top growth stocks are worth a second look.

Description: Eli Lilly (LLY) just crossed a $1 trillion market cap, capturing attention on Wall Street as diabetes and weight-loss drugs continue to propel the company’s value. Demand for its GLP-1 therapies, such as Zepbound and Mounjaro, has surged, due in part to strong clinical trial results and wider coverage from Medicare and Medicaid. See our latest analysis for Eli Lilly. Shares in Eli Lilly have soared over the past year, with momentum building thanks to breakthrough obesity and diabetes drug...

Description: Mizuho Americas healthcare equity strategist, Jared Holz, joins Market Catalysts host Julie Hyman to discuss Eli Lilly's (LLY) stock action, how the GLP-1 market has played a part, and whether Eli Lilly will see serious competition in the oral GLP-1 market moving forward. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: The possibility of adding a new Big Tech customer helped lift an American chipmaker's stock on Friday, Nov. 28, 2025, while a recently hot pharmaceutical stock cooled.

Description: Shares of U.S. chipmaker Intel were leading the S&P higher as stocks edged upward on a holiday-shortened Black Friday session expected to be light on trading volume and corporate news.

Description: Lithium miner Albemarle came out on top, while Super Micro Computer led the list of worst performers.

Description: Michelle Carnahan has spent the better part of the last three decades working in healthcare at companies like Thirty Madison and Eli Lilly (NYSE:LLY). Now, the entrepreneur has raised $52 million in seed money for her own startup, Arbiter, a platform that connects health care professionals and payers to provide better patient care. The money has all been raised from family offices, including TriEdge Investments, MFO Ventures, and WindRose Health Investors, according to the company's funding anno

Description: Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Description: Lilly have been highlighted in this Investment Ideas article.

Description: PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.

Description: NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.

Description: As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move.

Description: It's not only tech companies that can get to that market valuation.

Description: Eli Lilly recently became the first healthcare company to surpass a $1 trillion market capitalization, propelled by surging demand for its GLP-1-based diabetes and obesity drugs, Zepbound and Mounjaro, alongside significant pipeline developments and expanded Medicare and Medicaid coverage. This milestone reflects growing investor optimism about Eli Lilly's innovation pipeline, its manufacturing investments, and the potential for its upcoming oral obesity treatment to further transform the...

Description: Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.

Description: Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.

Description: ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.

Description: The stock recently reached beyond $1,000.

Description: GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.

Description: Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.

Description: We recently published 11 Stocks Jim Cramer Shared His Insights On. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top stocks in the pharmaceutical space. He has remained optimistic about the firm throughout the year and praised its lead in the weight […]

Description: U.S. government move slashes costs for key diabetes and weight-loss drugs beginning in 2027.

Description: The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks. Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation. Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.

Description: The weight loss drug market may approach almost $100 billion by the end of the decade.

Description: Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for Medium Term. On‍ November 18, JPMorgan analyst Chris Scho‍tt r‌aised the firm‍’s‍ price ta‌rg​et on Eli Lilly and Company (NYSE:LLY) to $1,150 from $1,050 wh‍ile maintaining an Overw‍eig​ht ratin⁠g after meetings with management. JPMorgan said the di‌scu‌ss⁠ions‌ re‌inforced its positive […]

Description: The US government has negotiated a 71 per cent discount for Novo Nordisk’s weight-loss drugs Ozempic and Wegovy for patients enrolled in Medicare...

Description: Good news from a GLP-1 receptor agonist clinical trial hit the market today.

Description: A promising next-gen diabetes treatment just gave Novo Nordisk its first real jolt of hope in months.

Description: Bernstein just threw fresh fuel on Eli Lilly's (LLY) never-ending rally, as the firm lifted its price target on the stock to $1,300 from $1,100. For perspective, that’s an 18% bump compared to the old target, while representing a 21% to 22% upside compared to Lilly’s current stock price. ...

Description: Shares, though, were punished Monday after the drug maker said its blockbuster obesity treatment Wegovy failed to slow Alzheimer’s.

Description: The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.

Description: We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying. Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, […]

Description: IYH hits a 52-week high as healthcare gains momentum, lifted by sector strength and rising investor interest in safety and AI-driven tailwinds.

Description: J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.

Description: As the U.S. stock market kicks off a holiday-shortened trading week with significant gains, investors are buoyed by optimism around a potential Federal Reserve interest rate cut in December. In this environment of heightened confidence, identifying stocks that may be undervalued compared to their estimated worth can be particularly appealing, as they offer opportunities for growth amidst broader market enthusiasm.

Description: Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

Description: LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.

Description: As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

Description: Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.

Description: Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12 in San Antonio, Texas. These updates reflect Lilly's continued progress across key pathways in hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer, the most common form of breast cancer.1

Description: The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.

Description: Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.3% and the H

Description: Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo Nordisk stock recently stood about 5.7% lower. The shares have tumbled by nearly three-quarters since hitting a peak at 1,028 Danish kroner in June last year.

Description: Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car

Description: The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.

Description: President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.

Description: Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9 in Orlando, Florida.

Description: Fuelled by weight loss drug sales, Eli Lilly achieves a feat no healthcare company has before.

Description: A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.

Description: Eli Lilly (LLY) is benefiting from the "broadening" GLP-1 market for obesity and type-2 diabetes, Mo

Description: A pill with the key ingredient in Ozempic and Wegovy didn’t slow Alzheimer’s disease in two late-stage clinical trials.

Description: Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.

Description: LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.

Description: The selloff in European defense stocks (BA.L, RHM.DE, HO.PA, BAB.L) deepens as hopes grow around a peace deal draft for Ukraine and Russia. China's robotaxi firm WeRide (WRD) rallies on a massive revenue jump - even though the firm is still burning cash. In pharma, after Eli Lilly (LLY) hit $1 trillion: Bayer (BAYN.DE) stock flies, Novo Nordisk (NVO, NOVO-B.CO) tanks. For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.

Description: Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.

Description: The stock market needs to show a lot of strength after damaging recent losses. Watch Nvidia, Apple and Eli Lilly.

Description: These Magnificent Seven players are well-positioned to benefit in the AI boom.

Description: Who says you have to choose between the two?

Description: The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

Description: The stock market rebounded Friday on Fed rate cut hopes but suffered damaging weekly losses. Nvidia, Apple and Eli Lilly are in focus.

Description: Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.

Description: Curious whether Eli Lilly’s stock is still a smart buy after its rapid rise? Let’s break down the numbers and see if the current price matches up with real value. Shares have vaulted higher lately, climbing 30.5% in just the last month and notching a stunning 40.2% gain over the past year. Investors are watching Eli Lilly closely after headline-making developments in its obesity and diabetes drug pipeline sent the stock to new highs. This reflects excitement over blockbuster potential and...

Description: The market has been swinging recently, with the S&P 500 index down 1.5% and the Nasdaq Composite down more than 2% over the past month. Investors are now questioning whether the tech momentum can continue. Some non-tech stocks have performed well, and Eli Lilly (LLY) is one of them. Eli ...

Description: A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia's life sciences ecosystem, higher-ed universities, and community colleges on October 31. This landmark public-private industry partnership commits $120 million of workforce inves

Description: Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.

Description: <body><p>STORY: Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progress of Alzheimer's disease.</p><p>Two trials have been described by Novo as a "lottery ticket".</p><p>They're testing its older diabetes pill that has the same active ingredient as Ozempic and Wegovy in thousands of people with mild Alzheimer's.</p><p>The goal is to decrease patients' rate of cognitive decline by at least 20%.</p><p>Alzheimer's experts say success would usher in a convenient new treatment to slow progression in a condition that affects 50 million people globally.</p><p>Researchers expect to glean important clues for future study into how and why these types of drugs, which include Eli Lilly’s Zepbound and Mounjaro, may be useful against the disease.</p><p>There are currently two drugs approved for slowing Alzheimer's by removing amyloid from the brain.</p><p>They are Lilly's Kisunla,  Leqembi from Eisai, and Biogen.</p><p>They were shown in clinical trials to slow disease progression by close to 30%.</p><p>Although they also carry the risk of serious side effects and require regular scans.</p><p>Novo is slated to present its results on December 3rd, although it could announce some data before then.</p></body>

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The "Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For

Description: Novo Nordisk just addressed a problem that has prevented some from taking these drugs.

Description: PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos Paya as Non-Executive Director. Carlos has a distinguished track record of leadership spanning academic medicine and the biopharmaceutical industry, with deep expertise in drug development and commercial strategy across early-stage start-ups to large-cap pharmaceutical companies.

Description: There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish their image a little more.

Description: Viking Therapeutics stock fell Wednesday after the company said it overenrolled one of its final-phase studies for its weight-loss shot.

Description: Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.

Description: FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.

Description: Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong technical momentum and is trading at new all-time highs. Shares are up 43% over the past year. Analyst sentiment is overwhelmingly positive, with most major firms rating LLY...

Description: The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for targeted therapies. Key innovations like immunotherapies, precision medicine, and early detection biomarkers are reshaping the market landscape, improving patient outcomes, and driving therapy adoption. Developed and emerging markets see enhanced care accessibility, propelled by investments in cancer i

Description: T. Rowe Price, a global investment management firm and a leader in retirement, announced the latest episode of "The Angle," an investment-themed podcast focused on timely topics shaping financial markets and featuring executives from some of the world's leading companies.

Description: Don't wait for a stock split to buy the stock, though.

Description: Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati

Description: ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.

Description: ​Novo Nordisk A/S (NYSE:NVO) is one of the Most Profitable Stocks to Buy Now. On November 17, Reuters reported that Novo Nordisk A/S (NYSE:NVO) will lower the US prices of its injectable Wegovy obesity drug. The price reduction for injectable Wegovy follows the company’s earlier announcement on November 6, where it agreed with the US […]

Description: Breakthrough Properties today announced that it has partnered with Eli Lilly and Company (Lilly) to launch Lilly Gateway Labs at Breakthrough at 2300 Market Street in Philadelphia. This new partnership provides innovative biotech companies comprehensive access to move-in ready labs, fully-equipped workspaces, and amenities they need to succeed and grow.

Description: Eli Lilly and Company (NYSE: LLY) today announced plans to open a new Lilly Gateway Labs (LGL) site in Philadelphia, bringing its distinctive model of scientific partnership to a city known for shaping the future of medicine.

Description: Eli Lilly and Company (LLY) shares up 15,892% since Big Money bought big in 1990.

Description: These stocks both have advanced in the double-digits in recent months.

Description: Microsoft posts strong cloud-fueled Q1 results as Azure surges and AI momentum builds, even as capacity limits pose near-term revenue constraints.

Description: Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed at a record, $973.8 billion, as Lilly inched closer to the $1 trillion market cap milestone.

Description: Microsoft shines in Zacks' top picks as strong cloud and AI momentum drive standout quarterly results and reinforce long-term growth potential.

Description: Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Description: Launch coming soon as India waits on final pricing plans

Description: Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.

Description: PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.

Description: Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m., Eastern time.

Description: We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s attention. Throughout 2025, the CNBC TV host […]

Description: Crypto caught in broad market selloff, food, restaurant companies feeling relief, U.S.-China trade deal is fragile, and more news to start your day.

Description: Eli Lilly might soon join them for a far different reason: the weight-loss bonanza. This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker Novo Nordisk That is why investors shouldn’t assume the rally stops at a trillion. Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.

Description: Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen reiterated its Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $960. This update came after the company announced an agreement with the US government to expand access […]

Description: Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.

Description: Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer expressed his thoughts on. A caller asked, as a long-time holder of substantial NVO shares that have significantly declined in value, if it is too late to exit the position. In response, Mad Money’s host said: “You gotta, okay, you gotta let it come […]

Description: Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.

Description: This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive trial news.

Description: Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Description: Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.

Description: The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.

Description: Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Description: The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the treatments between Nov. 17 and March 31.

Description: Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.

Description: Healthcare stocks have far outperformed the broader market over the past month.

Description: With significant upside potential, Structure Therapeutics Inc. (NASDAQ:GPCR) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. On November 10, 2025, BMO Capital reiterated its “Outperform” rating on Structure Therapeutics Inc. (NASDAQ:GPCR), setting a $100 price target. The firm cited upcoming ACCESS I and II Phase 2b […]

Description: Eli Lilly's stock has captured attention as consensus analyst price targets have risen from $919 to $1,003 per share. This shift underscores renewed optimism about the company's valuation prospects. The upward revision largely reflects analysts’ growing confidence in revenue growth, supported by robust demand for key treatments and steady execution across major franchises. As Wall Street continues to update its outlook in response to new data and market dynamics, readers will want to keep an...

Description: Investors will be watching what Trump makes happen.

Description: Drugs for weight loss and diabetes are taking Eli Lilly to new heights.

Description: We recently published 11 Stocks Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Cramer has again started to frequently discuss Eli Lilly and Company (NYSE:LLY) on his morning show. During the year’s first half, the CNBC TV host repeatedly praised the firm’s manufacturing initiatives and […]

Description: Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL) dominates the search engine market with a greater than 90% share, powering billions of daily queries through Google Search. Yet its growth extends beyond that core business. Google Cloud has captured a rising slice of the cloud computing sector, trailing only Amazon (NASDAQ:AMZN) and Microsoft (NASDAQ:MSFT), while investments in artificial intelligence position it ... Alphabet’s Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?

Description: Investing.com – The S&P 500 and Nasdaq are on track to close slightly higher this week, despite significant volatility.

Description: Eli Lilly (LLY) shares have shown steady momentum in recent weeks, not because of a single headline event, but rather due to investor focus on its long-term performance. The company’s growth has generated curiosity about its valuation. See our latest analysis for Eli Lilly. Momentum has clearly been building for Eli Lilly, with the share price climbing 24% over the last month and notching an impressive 38% total shareholder return for the year. Investors are paying attention to the company’s...

Description: Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05. Sometimes we see a divergence in share price and sentiment, but with Novo Nordisk they’re actually well correlated. Discussion on Reddit has remained uniformly bearish throughout November. Novo Nordisk is trading more than 50% ... Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

Description: ↗️ Alphabet (GOOGL): Warren Buffett’s Berkshire Hathaway added the Google parent company to its portfolio during the third quarter, according to a new disclosure late Friday. Alphabet shares rose 1.5% afterhours.

Description: The Standard & Poor's 500 index edged up 0.1% this week as gains led by health care and energy stock

Description: The UK considers raising NICE’s cost-effectiveness threshold, testing the balance between funding innovation and conserving NHS budget.

Description: The stock market continued its sell-off Friday, but a few stocks ascended in buy zones and hovered near new highs. Eli  Lilly, for one, hit an all-time high. Another is Valero, which has edged into a buy zone above an entry at 178.43, according to IBD MarketSurge.

Description: The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed board member, Mikael Dolsten, 67, withdrew just a day ago because of an “issue with a former employer.” “We had very much looked forward to working together with Mikael Dolsten,” Sorensen said. Pfizer’s acquisition of Metsera closed on Thursday making Novo and its US rival clear competitors in the hottest and fastest-growing pharmaceutical market.

Description: Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.

Description: The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Description: Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Description: Zacks Investment Ideas tracks market shifts as IWM strength, AI stock rotation and Nvidia's key support test shape year-end positioning.

Description: There is hardly a dull moment for the drugmaker these days.

Description: Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi's pioneering asset-centric investment model.

Description: The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.

Description: Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning titled “Mangoceuticals Partners with Eli Lilly and Novo Nordisk…”. The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 m

Description: The annual conference presented over 100 scientific sessions featuring innovations from leading pharmaceutical companies, including Novo Nordisk, Eli Lilly and Company, Viking Therapeutics, Ascletis Pharma, Skye Bioscience, Palatin Technologies, Inc., Neurogastrx, Inc., OrsoBio, Metsera, and others, revealing not only significant advances in drug efficacy but also reshaping the multibillion-dollar obesity therapeutics market. These presentations collectively demonstrate that obesity management h

Description: As traders position for year-end, the government shutdown is over, major market indices are filling gaps, and seasonal momentum looms.

Description: We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is the pharmaceutical giant best known for its weight loss drugs. Cramer regularly discusses the firm in his morning appearances […]

Description: We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the biggest healthcare and pharmaceutical companies in the world. The firm recently spun off its orthopedic business, and Cramer […]

Description: Key market opportunities in hypoglycemia therapeutics include leveraging the high incidence in India for market expansion and innovation, targeting the three Phase III pipeline assets for accelerated development, and capitalizing on recent strategic alliances and M&A activities to enhance competitive positioning.Dublin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The "Hypoglycemia: Market View" report has been added to ResearchAndMarkets.com's offering.This reports provides a data-driven overview of the c

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.

Description: Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) Released material under the Company’s Specials license for a second rare pediatric ophthalmology condition caused by mutations in BBS10, with the prescribing physician treating the first patient during the quarte

Description: Eli Lilly Dumps CVS Health Plan After Coverage Rift on Weight-Loss Drugs

Description: Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to announce that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (t

Description: These top growth stocks have plenty of room left to run.

Description: Healthcare stocks have plenty to offer new investors.

Description: Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher.

Description: Stock Market Today: The Dow Jones index rose Wednesday to new highs and AMD rallied sharply. Gold and silver stocks jammed.

Description: Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 1.6% and th

Description: Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.

Description: A 37% price cut, looming generics, and Lilly's Mounjaro surge turn India into the next $150B pharma battleground.

Description: The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 (Merck/Taiho/Astex Pharmaceuticals), Divarasib (Roche), Daraxonrasib (Revoltuion Medicines), Onvansertib (Cardiff Oncology), ELI-002 (Elicio Therapeutics), and others across the 7MM. G12C is the most prevalent KRAS mutation in NSCLC, making it a key target of current therapies. Following the success

Description: ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.

Description: Eli Lilly's strong price action and high ratings present a bull call spread trading opportunity with large profit potential and clearly defined risk parameters.

Description: Price reduction aims to regain ground in the world's most populous country.

Description: Companies in The News Are: SONY, SE, NVDA, LLY

Description: Recursion is about to go toe-to-toe with the largest healthcare company.

Description: Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Infineon Technologies (IFX.DE, IFNNY) raising its revenue guidance on AI data center demand, Chevron (CVX) choosing West Texas as the site of its first AI data center project, and Eli Lilly (LLY) reportedly dropping CVS Health's (CVS) drug plan from employee coverage. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: Investing.com -- Citi hiked its price target on Eli Lilly to $1,500 from $1,250, implying a potential upside of more than 50% from current levels, pointing to accelerating expectations for the company’s oral GLP-1 drug orforglipron. The bank reiterated a Buy rating on the stock.

Description: Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.

Description: The Dow Jones hit a closing high Tuesday, leading an ongoing stock market bounce. Palantir and Eli Lilly are in buy zones while AI stocks CoreWeave and Nebius sold off.

Description: Analyzing the Third Quarter 2025 13F Filing

Description: This drugmaker's innovation engine continues to operate at full capacity.

Description: SanegeneBio announced a global research and licensing collaboration with Eli Lilly to develop RNA interference therapies for metabolic diseases, leveraging SanegeneBio's LEAD™ platform for advanced, targeted delivery of RNAi drug candidates. This agreement, which includes up to US$1.2 billion in milestone and royalty payments, further strengthens Eli Lilly's pipeline in metabolic disease treatments and demonstrates the company's ongoing commitment to innovative therapies. We will now examine...

Description: The Dow Jones hit a closing high while the broader market held recent gains. Palantir and Eli Lilly are in buy zones. AI computing stocks CoreWeave and Nebius sold off.

Description: Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer offered insights on. Cramer discussed the future possibilities of the company’s weight loss drug, as he said: “… Eli Lilly, which I think has beaten back Danish Novo Nordisk, maybe even into submission. After all, Lilly’s on the market with a very effective […]

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer offered insights on. Cramer discussed the company’s acquisition of Metsera during the episode. He commented: “There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be bigger than others. This morning, the […]

Description: The European stock markets closed sharply higher for the second straight session in Tuesday trading

Description: Eli Lilly (LLY) stock is trading at record highs after the pharmaceutical company reached a deal with the White House to offer weight-loss drugs at a discount. Novo Nordisk (NVO), which was also part of Trump's GLP-1 deal, has not seen its stock climb to fresh record highs on the agreement. BMO Capital Markets' managing director of BioPharma equity research, Evan Seigerman, joins Market Catalysts with Julie Hyman to discuss the difference in stock reactions from the pharma giants. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: These three healthcare stocks are outperforming most of the sector.

Description: Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.

Description: Trifecta Health and Trifecta Med Spa are excited to announce two strategic cooperations aimed at improving patient access to high-quality obesity treatments. These cooperations will streamline the process for patients to receive FDA-approved medications directly from the manufacturers at the most affordable prices.

Description: For most of Big Pharma, drug discounts have largely been about damage control. After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief. For Eli Lilly’s   David Ricks and Novo Nordisk’s   Mike Doustdar, who paid their own visit to the White House last week, the calculus is different.

Description: Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.

Description: Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated deal with the White House. The move underlines Eli Lilly’s ambition to expand beyond its dominant ...

Description: The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.

Description: After losing out to Pfizer for a weight-loss drug startup, Novo Nordisk will now have to count more heavily on its own research labs for new drugs, even as it’s likely to continue to pursue other deals. Novo Nordisk’s near-term focus is to launch a pill form of Wegovy, the popular weight-loss drug it first launched in 2021 as a weekly injectable. Novo Nordisk has applied for Food and Drug Administration approval, and expects a decision by year end.

Description: Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.8% and the He

Description: Markets are coming back strong. All thanks to the news that the government shutdown may soon be over, which would remove a good deal of uncertainty in the markets. In fact, in the latest agreement, some Democrats and Republicans finally reached a vote of 60 to 40 to advance the vote to the next stage. ... Wall Street is Pounding the Table Over NVDA, RUN, LLY

Description: MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close in.

Description: Shares of Eli Lilly have not only bounced back from last week’s lows but have also surged to new highs as Wall Street digs into the implications of the company’s deal with the U.S. government. Lilly stock was up 4.8% at $969.14, putting it on pace for a record closing high, according to Dow Jones Market Data. Leerink Partners analyst David Risinger upgraded shares to Outperform from Market Perform and raised his price target to $1,104 from $886 in a note on Monday.

Description: Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.9% in the afternoon session after Leerink Partners upgraded the stock to Outperform from Market Perform and significantly raised its price target.

Description: Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Plug Power (PLUG) suspending its loan-guarantee initiative amid liquidity challenges, Eli Lilly's (LLY) new AI deal with Insilico Medicine, and Tyson Foods (TSN) topping fourth quarter adjusted earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

Description: <body><p>STORY: Shares in Novo Nordisk rose on Monday (November 10).</p><p>Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.</p><p>Market watchers saw its offer as too complex.</p><p>The Danish drugmaker has also come under more pressure over governance.</p><p>That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.</p><p>Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.</p><p>It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.</p><p>Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.</p><p>The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.</p><p>Metsera cited the antitrust concerns in rejecting Novo's bid.</p><p>The Danish drugmaker confirmed Saturday it would withdraw from the race.</p><p>Novo's shares were up 2.6% by Monday afternoon.</p><p>The stock has lost more than 70% of its value since June last year.</p></body>

Description: Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls

Description: Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly ("Lilly") that the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.

Description: Investing.com -- Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.

Description: For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and advocate, he's spent years helping people express their individuality through what they wear. But he's also seen first-hand the stigma carried by people living with obesity, amplified by society's misunderstanding of the science behind the chronic disease and the persistent belief that obesity is simply a failure of willpower.

Description: Pre-Market Stock Futures: The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close. Hopes that an end to the Government shutdown in Congress is driving the futures higher this morning. The same mantra that was chanted last week — AI/Bubble, stocks ... Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More

Description: With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?

Description: LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”). MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) owing to genetic deficiency of Aryl-hydrocarbo

Description: Walmart recently expanded its health and wellness offerings by partnering with Eli Lilly to provide direct-to-consumer access for the weight-loss drug Zepbound in its pharmacies, while also integrating GOFO's nationwide logistics services to strengthen its e-commerce marketplace delivery capabilities. These collaborations underscore Walmart’s drive to enhance healthcare access and delivery efficiency, reflecting a multi-faceted approach to digital transformation and marketplace...

Description: For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

Description: Eli Lilly, the weight-loss drug heavyweight, joins AI stocks CrowdStrike Holdings and Semtech on this weekend's watchlist of five stocks near buy points. CrowdStrike is a leader in the emerging area of AI-driven security, while Semtech's data-center chips facilitate high performance with low power consumption. Lilly has a 99 IBD Composite Rating out of a possible 99, according to IBD Stock Checkup.

Description: The stock didn't stay down for too long.

Description: <body><p>STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.</p><p>It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race. </p><p>Metsera accepted a sweetened offer from Pfizer late Friday (November 7). </p><p>It cited U.S. antitrust risks in Novo's bid that it had previously called superior. </p><p>Novo said in a statement that it believed its offer structure was "compliant with antitrust laws."</p><p>Metsera’s drugs are projected to reach $5 billion in peak sales.</p><p>And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves. </p><p>It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.</p><p>The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…</p><p>And that it would "continue to assess opportunities for business development and acquisitions”.</p><p>Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.</p></body>

Description: It could become the first trillion-dollar pharmaceutical company in the process.

Description: SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("Lilly"). The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio's proprietary tissue selective delivery technology, LEAD™ (Ligand and Enhancer Assisted Delivery).

Description: Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.

Description: Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer mentioned the stock during the episode and commented: “I do believe that there are very few biotechs that I really want to buy right now because they’re so picked over. Look, in the end, there’s Eli Lilly and […]

Description: Find insight on Eli Lilly, Novo Nordisk, AstraZeneca, Hikma Pharmaceuticals in the latest Market Talks covering the Health Care sector.

Description: Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) fell 4.1% in the afternoon session after the stock retreated amid renewed concerns about stretched valuations in the AI space and geopolitical concerns as the U.S. government reportedly moved to block the company from selling even its less powerful, scaled-down artificial intelligence chips to China. The decision was aimed at stopping the sale of a reconfigured version of the advanced Blackwell chip, which had been designed specif

Description: Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?

Description: Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.

Description: Eli Lilly stock is nearing a buy point and a high. The White House signed a historic deal to slash obesity drug prices.

Description: NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.

Description: <body><p>STORY: Novo Nordisk shares fell as much as 3% on Friday (November 7) before scaling back.</p><p>Investors sold off after the Danish drugmaker and U.S. rival Eli Lilly announced a pricing deal with the U.S. government on Thursday (November 6).</p><p>They have agreed to lower prices of their popular weight-loss drugs, including Novo's Wegovy and Lilly's Zepbound.</p><p>It should lower monthly prices for cash payers and U.S. government programs like Medicare and Medicaid.</p><p>It reduces the prices to between $149 and $350, down from its current $500 to $1,000.</p><p>The deal also gives the companies a three-year relief from tariffs.</p><p>Analysts expect the price cuts to hit short-term revenue, but potentially boost volumes long term.</p><p>It come as Novo faces growing competition in the weight-loss drug market, where Lilly's Zepbound and copycat drugs have gained ground.</p><p>Novo was first to market when it launched Wegovy four years ago, and briefly became Europe's most valuable listed company as demand boomed.</p><p>But its market value has plunged 70% since last year due to supply constraints and commercial challenges.</p><p>Novo said the lower prices would have a negative "low single-digit" impact on global sales growth next year.</p><p>It added bigger volumes under Medicare were expected in the mid- to long term.</p></body>

Description: Pharma rivals fight for control of next-generation obesity drug maker

Description: Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS therapies, today announced the appointment of Laurent Fischer, MD, as its first independent Chair of the Board of Directors, alongside the company's first data presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in National Harbor, MD from November 5-9, 2025. These milestones collectively reflect Shinobi's continued momentum as it advances its oncology and autoimmun

Description: Partnership with Trump administration aims to expand Medicare and Medicaid access

Description: This update comes at a time when rivalries in the obesity market are heating up.

Description: Investing.com -- Shares of Novo Nordisk are down 2.5% on Friday after the Trump administration announced agreements with the Danish drugmaker and Eli Lilly to cut prices for GLP-1 drugs used to treat diabetes and obesity.

Description: AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

Description: The deals, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to more people on Medicare, the government health plan for older Americans. “It’s a triumph for American patients that will save lives and improve the health of millions and millions of Americans,” Trump told reporters in the Oval Office.

Description: US President Trump announced deals with Novo Nordisk (NVO) and Eli Lilly (LLY) to secure lower prices of the companies' GLP-1 drugs. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination Overtime host Josh Lipton to take a closer look at what the deals mean for the companies. Breen also discusses Pfizer's (PFE) legal case to block Novo Nordisk's (NVO) Metsera (MTSR) acquisition. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: The deals, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to more people on Medicare, the government health plan for older Americans. “It’s a triumph for American patients that will save lives and improve the health of millions and millions of Americans,” Trump told reporters in the Oval Office.

Description: <body><p>STORY: "I think initially, [stocks] rallied on the idea that, 'Hey, we're going to have the opportunity to sell more of this product to more and more people, that should be good for us," Landsberg said, after the deal was announced.</p><p>But later in the day, he noted that investors may be having "a second thought saying, 'But what if the U.S. government's in there [and they're] gonna really drive down some of our margins?"</p></body>

Description: The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their weight-loss drugs.

Description: Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines.

Description: SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali’s Board of Directors. Mr. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx. Carole Ho, M.D., who has served as Denali’s Chief Medical Officer and Head of Development since 2015, will be departing to join Eli Lilly and Company as Executive Vice Pr

Description: Eli Lilly (LLY) and Novo Nordisk (NVO) will reduce US prices for their popular weight-loss and diabe

Description: The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.

Description: Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer was asked about. Mentioning that they are a long-term shareholder of VKTX, a caller said that they have been observing the bidding war between Novo Nordisk and Pfizer for Metsera. Cramer commented: “Yeah, I know, and I’ve watched that, and I don’t, I think […]

Description: Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines. In 2020, Lilly partnered with the Trump Administration on a pilot program that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improv

Description: America's waistline may shrink, but its national debt will swell.

Description: (Updates with additional details in the third to fifth paragraphs.) Eli Lilly (LLY) and Novo Nord

Description: Ever wondered if Eli Lilly's stock is offering genuine value, or if the price is running ahead of itself? Let’s dig into what’s happening beneath those eye-catching numbers. Shares have climbed an impressive 13.8% in just the last week, and are up 20.2% over the past year, showing that investors remain bullish, while possibly adjusting their risk and reward expectations. Recent headlines have amplified optimism about Eli Lilly’s drug pipeline, including FDA progress for obesity and diabetes...

Description: Yahoo Finance's John Hyland tracks Thursday's top moving stocks and biggest market stories in this Market Minute. Eli Lilly (LLY) and Novo Nordisk (NVO) will lower GLP-1 prices as a result of newly made agreements with the Trump administration. Airline stocks, including United (UAL), American (AAL), and Delta (DAL), are falling after the FAA announced a 10% decrease in flight traffic amid the government shutdown. Ralph Lauren (RL) stock is under pressure even after the company reported second quarter results that topped analyst estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: Eli Lilly & Co. and Novo Nordisk A/S cut a deal with the Trump administration to lower prices on their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. President Donald Trump spoke about it in the Oval Office.

Description: Popular GLP-1 drugs like Ozempic will get cheaper in exchange for partial Medicare coverage, opening up new markets for Eli Lilly and Novo Nordisk

Description: Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, which is expanding coverage of the drugs in the Medicare and Medicaid health-insurance programs. The companies will sell their GLP-1-containing drugs, including Novo Nordisk’s Ozempic and Wegovy, and Eli Lilly’s Mounjaro and Zepbound, to the Medicare and Medicaid programs for $245 a month, to treat both diabetes and obesity, according to senior administration officials.

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

Description: Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.

Description: Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

Description: DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: Novo Nordisk stock reversed higher Wednesday, though the Wegovy and Ozempic maker cut its sales outlook for the third time this year.

Description: RESEARCH TRIANGLE PARK, N.C., November 05, 2025--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.

Description: Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 0.4% and th

Description: The Alliance for Building Better Medicine (ABBM) and the Virginia Innovation Partnership Corporation (VIPC) celebrated Governor Glenn Youngkin's announcement of $120 million in private industry investment from AstraZeneca, Eli Lilly, and Merck to establish the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) in the Richmond-Petersburg-Charlottesville region. This neutral, industry-led Center will expand Virginia's workforce and training pipeline in collaboration with university an

Description: A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance. Will it continue?

Description: Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the Health

Description: Novo Nordisk Stock Slips as Forecast Cut Overshadows Strong Q3 Results

Description: AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.

Description: The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

Description: NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: IHE just hit a 52-week high. The ETF is up nearly 30% from its low, powered by $LLY's 9.6% past week surge and bold expansion plans. More upside ahead?

Description: The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.

Description: The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Description: Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.

Description: Eli Lilly (LLY) has asked European nations to discard clawback taxes on drug sales, Hannah Kuchler of The Financial Times reports. As the Trump administration pushes for a policy that would lower drug prices in the U.S. to match the cheapest levels in other developed nations, Lilly CEO David Ricks said the company will lower U.S. costs while raising them in Europe to equalize the drug prices. The pharma industry has been dealing with UK’s clawback tax, where a certain percent of revenue above a

Description: Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter.

Description: Metsera on Tuesday called Novo Nordisk’s new $10 billion offer “superior” to rival Pfizer's bid of $8 billion.

Description: Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Description: The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more heated.

Description: Precision oncology is tailoring treatments based on molecular profiles, while new surgical and radiotherapy methods boost recovery. Despite challenges like late diagnosis and high treatment costs, leading pharmaceutical companies are driving therapeutic innovation. Strategic alliances and investments in clinical trials are expected to enhance access to new treatments globally.Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Gastric Cancer Market - A Global and Regional Analysis: Focus on Treatment

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Description: Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: FERNANDINA BEACH, Fla., November 04, 2025--The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, has launched the Lp(a) AW(a)RETM initiative to engage key U.S. healthcare stakeholders in advancing awareness, screening and diagnosis of high Lipoprotein(a) – also known as Lp(a). It is estimated that approximately 20% of the U.S. population has a genetic mutation for high Lp(a), yet only 1% in the general population, and 2% with est

Description: Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.

Description: Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]

Description: Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist.

Description: While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

Description: Find insight on Eli Lilly, Kimberly-Clark’s deal to buy Kenvue and more in the latest Market Talks covering the Health Care sector.

Description: Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.

Description: The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

Description: RICHMOND, Va, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), congratulates Governor Glenn Youngkin, the Virginia Innovation Partnership Corporation (VIPC), and several leading Virginia universities on the recent announcement of a $120 million investment from AstraZeneca, Eli Lilly and Company, and Merck to expand Virginia’s life sciences and advanced pharmaceutical manufacturing workforce devel

Description: Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.

Description: The healthcare industry is chock-full of opportunities for long-term investors.

Description: George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.

Description: Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Description: The stock market has continued to climb, but it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.

Description: Eli Lilly & Company (NYSE:LLY) ranks among the stocks with the best earnings growth for the next 5 years. Cantor Fitzgerald reaffirmed its Overweight rating and $925 price target for Eli Lilly & Company (NYSE:LLY) on October 17 following the exclusion of the company’s oral GLP-1 treatment, orforglipron, from the first group of medications to […]

Description: Now is a great time to be shopping for stocks that can anchor your portfolio.

Description: Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the company’s intrinsic valuation amid evolving market sentiment. The upward revision follows robust quarterly performance and optimism for future revenue growth, even as projections have moderated slightly. Stay tuned to discover how ongoing developments and shifting analyst views will continue to shape perspectives on Eli Lilly’s stock narrative. Analyst Price Targets don't...

Description: Eli Lilly and Company ( NYSE:LLY ) defied analyst predictions to release its quarterly results, which were ahead of...

Description: Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Description: The stock market has continued to climb. But it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.

Description: We recently published 10 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) continues to be one of Cramer’s top pharmaceutical stocks. He has consistently discussed the firm in 2025 and praised it on several fronts. These include Eli Lilly […]

Description: Three S&P 500 components, including JPMorgan Chase and Eli Lilly, are among five stocks near buy points.

Description: The AI chip darling already has the most cutting-edge products and the best customers. The next thing to do is to find more of them.

Description: Eli Lilly (LLY) delivered standout results, with earnings climbing at a 20% annual pace over the past five years and surging 120% in the last year alone. Net profit margins rose to 31% versus 20.5% a year ago. Looking ahead, earnings are forecast to grow at 19.3% per year, outpacing the broader US market's 15.9% estimate. Despite a lofty Price-to-Earnings ratio of 42 times, which sits well above industry norms, the current share price of $862.86 still trails a discounted cash flow fair value...

Description: The stock market has continued to rise. But it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.

Description: After the Nasdaq sets a seven-year record, a slew of high flying stocks report in the coming week. Plus there's a bonus day from Tesla.

Description: BD8 Capital Partners CEO and CIO, Barbara Doran, joins Market Domination host Josh Lipton to discuss the biggest earnings results that were posted this week, artificial intelligence (AI) demand, and her top three stock picks. To watch more expert insights and analysis on the latest market action, check out more Market Domination.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Eli Lilly (LLY) stock has continued its gradual ascent this month, building on a year marked by steady performance. Investors interested in healthcare stocks may be taking note of its consistent growth, especially as momentum in the biotech sector picks up. See our latest analysis for Eli Lilly. Eli Lilly’s share price recently surged 10.7% over the past month, a move that has added to its solid year-to-date momentum. While the 1-year total shareholder return stands at just 2.6%, the...

Description: Eli Lilly (LLY) is producing weight-loss pills ahead of US approval to prepare inventory for when the product enters the market. Eli Lilly CFO Lucas Montarce talks to Yahoo Finance about Eli Lilly's expectations for the drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Eli Lilly (LLY) delivered another solid quarter, citing strong international demand for type 2 diabe

Description: <body><p>STORY: :: Novo Nordisk </p><p>Novo Nordisk has almost completed notifying employees impacted by the drugmaker's 9,000 job cuts.</p><p>That’s according to a LinkedIn post by CEO Mike Doustdar Friday. </p><p>As jobs were slashed globally, he added that the pace of informing people varied according to local laws. </p><p>It’s part of Doustdar’s restructuring drive which he launched last month. </p><p>And comes as Novo faces heated competition in the United States, the world's biggest drug market, against rival Eli Lilly.</p><p>The $150 billion weight-loss drug market is booming and Novo’s setting its sights on newer heights.  </p><p>:: Pfizer </p><p>The Danish pharma giant and another major rival Pfizer are in a bidding war over obesity biotech Metsera’s hottest experimental treatments. </p><p>The drugmakers are vying for access to its once-monthly GLP-1 injectable.</p><p>Current popular injectables, including Novo’s Wegovy and Eli Lilly’s Zepbound, are weekly shots. </p><p>Metsera is one of several companies developing experimental weight-loss drugs.</p><p>The move signals an aggressive turn by Novo Nordisk a week after the ousting of most of the company's board.</p><p>That was over concerns it was not moving fast enough in the obesity market.</p></body>

Description: Companies in The News Are: WDC,LLY,IP,CAH

Description: Mounjaro and Zepbound sales fuelled Eli Lilly’s strong Q3, which surpassed analyst forecasts.

Description: Tech futures rose on Amazon, Apple and other earnings winners late after Meta led stocks lower Thursday.

Description: Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Desmoid Tumors Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.One of the key drivers of the Desmoid Tumors market is the advancement of targeted therapies. As the understanding of the molecular and genetic drivers of Desmoid Tumors improves, companies are developing more precise, personalized treatments that target the specific pathways invo

Description: The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company’s "high internal bar for success," a spokesperson said.

Description: With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

Description: The United States agreed to reduce broad tariffs on Chinese imports by 10 percentage points, bringing them to 47%.

Description: Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

Description: Execs said that inflation-addled consumers are under the impression that Chipotle costs more than it does.

Description: According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.

Description: The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug market.

Description: Tech futures rose on Amazon, Apple and other earnings winners late after Meta led stocks lower Thursday.

Description: Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic growth initiatives.

Description: Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma’s hottest.

Description: 1329 ET – Eli Lilly’s direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call. “There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system,” Lily USA President Ilya Yuffa says. “We’re seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct.”

Description: Stock Market Today: The Dow Jones index rises while the Nasdaq drops with Meta stock plunging. Chipotle sinks.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: ↘️ Chipotle Mexican Grill (CMG): The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were turning customers away from its stores. Shares slid 18% Thursday.

Description: Eli Lilly stock rose early Thursday after the drugmaker easily topped third-quarter forecasts on the back of its two biggest drugs.

Description: Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.

Description: Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The pharmaceutical company also announced a partnership with Walmart (WMT) to make GLP-1s more accessible to consumers. Eli Lilly CFO Lucas Montarce joins Market Catalysts to discuss the pharmaceutical giant's earnings print and its Walmart partnership. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.

Description: Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the company reported a "beat and raise" quarter.

Description: Two of the world’s largest pharmaceutical companies are locked in a bidding war for the maker of a weight-loss drug that could help patients avoid succumbing to “Ozempic face”.

Description: Eli Lilly (LLY) is one of Nvidia's (NVDA) many partners announced by the artificial intelligence (AI) chipmaker. The two companies are teaming up to build a supercomputer for drug discovery. Eli Lilly CFO, Lucas Montarce, explains how the partnership will help the pharmaceutical company grow. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.

Description: Massive Earnings Surprise Sends Eli Lilly Stock Higher

Description: Earnings Data Deluge

Description: Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter. Separately, Danish drugmaker Novo Nordisk announced plans to buy Metsera Inc. in a deal that could be worth up to $9 billion.

Description: Weekly Jobless Claims are not out again this Thursday morning, for the fifth straight week.

Description: The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, October 30, including earnings results from Big Tech names Apple (AAPL) and Amazon (AMZN), commentary from the Federal Reserve's Michelle Bowman, and the latest mortgage rates reading. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: The drugmaker Eli Lilly reports its third-quarter results early Thursday, as questions loom about what kind of deal it will reach with the Trump administration over the price of its weight-loss drug. Lilly shares are up about 5% this year. Lilly appears to have triumphed over Novo Nordisk in the battle for the weight-loss market.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Nvidia became the first company to hit $5 trillion in market value, the latest milestone in an unprecedented surge that reflects the growing influence of artificial intelligence on markets and the economy. The chip maker’s stock rose about 3% Wednesday to $207.16, giving it a market cap of $5.03 trillion. Shares have been boosted by exuberance for AI’s potential and a recent flurry of deals and partnerships with some of the biggest companies in AI and corporate America, from OpenAI and Oracle to Nokia and drugmaker Eli Lilly Enthusiasm for Chief Executive Officer Jensen Huang’s speech in Washington, D.C., also juiced gains this week.

Description: Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index decreasing 0

Description: Move strengthens U.S. production and supports new obesity drug pipeline

Description: The partnership is the latest in a long line of AI-centric projects in drug discovery and development.

Description: Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index easing 0.1% and t

Description: Look beyond big technology at stocks in other areas like big pharma, infrastructure, energy and aerospace.

Description: Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently provided insights on. Cramer highlighted it as the most valuable health care company and commented: “Now, let’s talk about the real contenders, okay. Let’s start with Eli Lilly, one I always said was going to get to trillion dollars, but it’s really […]

Description: Eli Lilly and Company (NYSE: LLY) announced today a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico. This new investment will integrate advanced technologies and expand production capacity within the existing campus to support the company's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology.

Description: Nvidia on Wednesday became the fist company with a $5 trillion market cap.

Description: LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.

Description: Discover the best credit cards to save money, earn rewards and travel smarter.

Description: Eli Lilly and Company (NYSE: LLY) and Walmart Inc. (NYSE: WMT) today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect. Zepbound (ZEHP-bownd) vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November. LillyDirect's direct-to-consumer pricing, or self-pay pricing, offers a 50% or greater discount compared to the list price of other incretin (GLP-1) medicines for obesity.

Description: It offers compelling weight-loss drugs -- and a compelling stock price, too.

Description: This stock has caught fire after some recent events, but how long will that last?

Description: Stock indexes hit fresh record highs, boosted by AI deals and earnings. Nvidia shares rose after unveiling new partnerships, while UnitedHealth, UPS and PayPal reported strong earnings. The Dow industrials rose 162 points, while the S&P 500 rose 0.2% and the Nasdaq Composite climbed 0.8% (🎧 listen here).

Description: After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is on Novo to pull off a major about-face.

Description: Global pharmaceutical company Eli Lilly (NYSE:LLY) will be announcing earnings results this Thursday before market open. Here’s what investors should know.

Description: Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Rising Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is seen as a strong heal‌thc‌a‍re stock that investors can confidently hold for many years. Known f⁠or its‌ long track recor​d of in​novation⁠ and extens​ive drug pip⁠eline, the Indian‌apolis-based pharmaceutica‌l com​pany​ boasts im⁠pr​essive […]

Description: On October 27, 2025, Eli Lilly announced that the U.S. FDA approved a new, once-monthly single-injection maintenance regimen of Omvoh (mirikizumab) for adults with moderately to severely active ulcerative colitis, simplifying patient treatment and supporting global immunology portfolio expansion. This regulatory milestone coincides with new Phase 3 clinical data showing Omvoh’s efficacy in improving key patient symptoms, enhancing both product differentiation and potential uptake in a...

Description: This momentary pullback represents an excellent opportunity to buy this high-flying stock.

Description: US stock futures held near flat with investors eyeing the upcoming Fed policy decision following another record-setting session on Wall Street.

Description: The Blackwell processor, Nvidia’s flagship artificial intelligence accelerator, and the newer Rubin model are fueling an unprecedented surge of sales growth through 2026, Huang said Tuesday at a company presentation in Washington. The event — Nvidia’s first GTC conference held in the nation’s capital — highlighted the partnerships that the company is forging across the industry.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Stock indexes hit fresh record highs, boosted by AI deals and corporate earnings. Nvidia rose after unveiling new partnerships at an event in Washington, D.C., while UnitedHealth, UPS and PayPal reported strong earnings. Nvidia’s valuation rose to nearly $5 trillion.

Description: Nvidia (NVDA) CEO Jensen Huang announced a slew of partnerships at the artificial intelligence (AI) chipmaker's annual conference, including with the US Department of Energy, Uber (UBER), Eli Lilly (LLY), Palantir (PLTR), CrowdStrike (CRWD), and more. Futurum CEO Daniel Newman joins Market Domination to discuss what the new partnerships mean for Nvidia and the AI space at large. To watch more expert insights and analysis on the latest market action, check out more Market Domination.

Description: Behind the gains were several new deals and enthusiasm for CEO Jensen Huang's speech in Washington, D.C. Nvidia has teamed up with drugmaker Eli Lilly to build what the companies say will be the most powerful supercomputer run by a pharmaceutical company to boost the discovery of new medicines. Huang unveiled NVQLink, an interconnect that links quantum processors to the AI supercomputers they need to run effectively.

Description: Nvidia stock surged after a slew of announcements at its GTC event, putting the company on track to be the first in history to cross the $5 trillion market cap milestone.

Description: Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) jumped 5.2% in the afternoon session after CEO Jensen Huang laid out an overwhelmingly bullish case for the company's future at a landmark GTC keynote in Washington, D.C.

Description: Using the supercomputer, scientists at Lilly will be able to train AI ‌models on millions of experiments to test potential medicines, expanding the scope of drug discovery efforts, the company said. A number of these proprietary AI models will be available on Lilly TuneLab, a federated artificial-intelligence ⁠and machine-learning platform that ‌allows biotech companies access to drug discovery models trained on years of its research data. The federated model is a ‍privacy-preserving approach that enables biotechs to tap into Lilly's AI models without directly exposing either their or Lilly's proprietary data.

Description: Nvidia announced on Tuesday that drugmaker Lilly is developing an AI system using more than 1,000 Blackwell Ultra chips.

Description: Eli Lilly and Company (NYSE: LLY) today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with NVIDIA. The supercomputer will power an "AI factory," a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference.

Description: The drugmaker hopes an Nvidia-chip powered supercomputer will help it find new drugs and accelerate lengthy R&D timelines.

Description: Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index shedding 0.5% and the

Description: International Business Machines Corporation (NYSE:IBM) is one of the stocks on Jim Cramer’s radar recently. Starting the round of “Am I diversified?”, a caller noted that their top five holdings are Apple, IBM, Chevron, Eli Lilly, and Verizon, and asked if their portfolio is diversified enough. Cramer replied: “You can tell Leslie’s watched a lot […]

Description: Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

Description: Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC).

Description: The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock.

Description: Eli Lilly and Company (NYSE: LLY) today announced a new partnership with NBA Hall of Famer and cultural icon Shaquille O'Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA). The initiative aims to educate the public about the symptoms and potential health impacts of moderate-to-severe OSA, a serious but often overlooked health condition that impacts 24 million people in the U.S., many of whom are overweight or living with obesity.

Description: This pharma giant is entering the rapidly expanding market for weight loss drugs.

Description: Eli Lilly and Company (NYSE:LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the company needs to find a new use for its GLP-1 drug, as he stated: “How about Eli Lilly? Now, I hate to say it, but it’s become luckless. If the company doesn’t […]

Description: As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Description: Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy.

Description: Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.

Description: Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Description: For Adverum, the potential buyout from Eli Lilly provides financial respite.

Description: Long-term investors don't need to rush to buy Eli Lilly stock.

Description: New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh-treated patients with moderately to severely active ulcerative colitis (UC) and bowel urgency experienced early improvements in bowel urgency severity, frequency and stool deferral time by Week 12. These outcomes continued to improve through 28 weeks. The Phase 3b single-arm, open-label LUCENT-URGE study was specifically designed to assess bowel urgency and is the first in inflammatory bowel disease to include the novel endpoints of bo

Description: The Goldman Sachs MSCI World Private Equity Return Tracker ETF does its best to replicate PE performance with publicly traded stocks.

Description: Avidity Biosciences (RNA) has agreed to be acquired by Novartis (NVS) for $72 per share in a deal th

Description: New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals for expanded use based on these results. See our latest analysis for Incyte. Incyte’s momentum has really picked up this year thanks to positive trial results and recent pipeline updates, such as its advances in atopic dermatitis and cancer immunotherapies. The stock’s strong 31% share price...

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come next week, including earnings results from Magnificent Seven companies Microsoft (MSFT), Amazon (AMZN), Apple (AAPL), Alphabet (GOOG, GOOGL), and Meta Platforms (META); Federal Reserve officials convening for their October FOMC meeting; and President Trump is meeting Chinese President Xi Jinping in South Korea as the government shutdown nears its fifth week. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: Adverum Biotechnologies' (ADVM) deal to be acquired by Eli Lilly (LLY) represents a likely "best pos

Description: All three major US stock indexes were up in late-morning trading Friday after the latest consumer pr

Description: Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.

Description: <body><p>STORY: A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation.</p><p>It's rattling investors despite calls for stronger leadership at the drugmaker behind weight-loss treatment Wegovy.</p><p>Once Europe's most valuable firm thanks to the blockbuster obesity drug, Novo Nordisk has stumbled in the last year.</p><p>Slowing sales and intensifying competition from U.S. rival Eli Lilly have eroded its market share.</p><p>The Novo Nordisk Foundation holds more than three-quarters of the firm's voting shares.</p><p>This week it pushed out Novo's board chairman and independent members for not acting quickly enough to stem the decline in its key U.S. market.</p><p>Foundation chair Lars Rebien Sorensen - a former long-time Novo chief executive - will also become the company board chairman.</p><p>The dual role is unprecedented in the firm's history.</p><p>One analyst told Reuters that the move showed the Foundation was in full control.</p><p>The Novo Nordisk Foundation says on its website that it plays an "arm's length" role in the company.</p><p>It was set up to ensure financial and strategic stability of the Novo Group.</p><p>While advancing scientific research and humanitarian causes.</p><p>Novo's shares are down around 5% since the board shake-up.</p><p>Extending a decline that has seen the stock lose two-thirds of its value since a 2024 peak.</p><p>Its CEO is now leading a sweeping restructuring, including thousands of job cuts.</p></body>

Description: Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.

Description: Eli Lilly (LLY) has agreed to acquire Adverum Biotechnologies (ADVM), which is developing a therapy

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Eli Lilly's (LLY) deal to acquire Adverum Biotechnologies (ADVM), gold miner Newmont's (NEM) cost-cutting initiatives, and General Dynamics (GD) shares moving to an all-time record high following its latest earnings results fueled by jet demand. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Insights into Eaton Vance's Strategic Moves in the Healthcare Sector

Description: INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.

Description: LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.

Description: Eli Lilly (LLY) has agreed to acquire Adverum Biotechnologies (ADVM) including its lead product cand

Description: Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adverum Biotechnologies, Inc. ("Adverum"), including its lead product candidate, Ixo-vec.

Description: Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s query about the stock during the episode, Cramer said: “Here’s the problem with Lilly: they need to have something else to come out. They need something that’s big that the insurance companies will cover, for their […]

Description: Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the company’s previous closing share price.

Description: As major U.S. stock indexes recently ended lower amidst ongoing earnings reports and renewed U.S.-China trade tensions, investors are keenly observing market fluctuations for potential opportunities. In such an environment, identifying undervalued stocks can be a strategic approach, as these equities might offer a margin of safety and potential for appreciation when market conditions stabilize or improve.

Description: New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. These 52-week results from the BRAVE-AA-PEDS trial – the largest Phase 3 study of its kind – will be presented at the 2025 Fall Clinical Dermatology (FCD) Conference, taking place Oct. 23-26 in Las Vegas.1

Description: New results show Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) sustained similar levels of skin clearance when administered as a single injection of 250 mg once every eight weeks (Q8W) compared with once every four weeks (Q4W), supporting a potential additional, less frequent maintenance dosing option for more individualized treatment of patients with moderate-to-severe atopic dermatitis. These findings from the Phase 3 ADjoin extension trial will be presented at the 2025 Fall

Description: Even aggressive tariffs may prove unable to stop this high-flying stock.

Description: Viking Therapeutics stock popped Thursday on the lightning pace it's enrolling patients in a pair of obesity treatment tests.

Description: Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025–2033. The radiop

Description: Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.

Description: Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.

Description: A board shake-up at Novo Nordisk has blindsided the market and concentrated power in the hands of one man at the top of one of Europe’s biggest...

Description: We recently published 10 Trending Stocks Moving These Days. Novo Nordisk A/S (NYSE:NVO) is one of the trending stocks moving these days. Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the company’s weight-loss drug business. “All this talk about GLP-1s? No, I’m not […]

Description: Since April 2025, Eli Lilly has been in a holding pattern, posting a small loss of 2.2% while floating around $811. The stock also fell short of the S&P 500’s 24.7% gain during that period.

Description: Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P. Morgan analyst Chris Schott maintained a bullish stance on Eli Lilly and Company (NYSE:LLY), keeping his Buy rating. The same day, Eli Lilly and Company (NYSE:LLY) announced results from the primary overall […]

Description: Thinking about what to do with Eli Lilly shares? You’re certainly not alone. The stock has been climbing the leaderboard for years, with a staggering 554.4% return over five years and 132.8% gains for anyone holding on since mid-2021. But if you’ve checked your portfolio lately, you might have noticed a few unexpected moves. Over the last month, Lilly edged up 7.6%, even in the face of a minor 1.7% slip for the week. For the year, it’s showing a modest 4.4% climb, but that’s coming off last...

Description: Guardant Health received FDA approval for its Guardant360 CDx blood test as a companion diagnostic for Eli Lilly’s Inluriyo, targeting advanced breast cancer patients with ESR1 mutations. This regulatory milestone positions Guardant Health at the center of precision oncology, potentially enhancing both patient treatment options and the company's clinical impact. We'll explore how this FDA approval for Guardant360 CDx could reshape Guardant Health's investment narrative and growth...

Description: Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.

Description: The rapid growth rates of recent years aren't guaranteed to continue.

Description: Donald Trump’s administration is stepping up attacks on US trading partners over drug pricing, preparing a new probe that would lay the ground...

Description: We came across a bullish thesis on Eli Lilly and Company on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $724.54 as of September 26th. LLY’s trailing and forward P/E were 47.36 and 24.04 respectively according to Yahoo Finance. Few companies […]

Description: <body><p>STORY: Novo Nordisk’s top shareholder moved to take control of the company’s board Tuesday in an effort to revive sales of its blockbuster weight-loss drug Wegovy in the key U.S. market.</p><p>It comes as the board chair and six other board members quit.</p><p>The non-profit Novo Nordisk Foundation, which combines business ownership with philanthropy, said it would propose former CEO Lars Rebien Sorensen as chair to lead the Danish drugmaker's board for the next two or three years.</p><p>The clash brings fresh upheaval to a company that soared to become Europe's most valuable company last year on the huge success of Wegovy.</p><p>This year, the stock has plunged more than 40% as rival Eli Lilly grabbed market share.</p><p>The foundation criticized the outgoing board for being too slow to recognize shifts in the key U.S. market and too cautious on management change.</p><p>However, the foundation is still backing CEO Mike Doustdar who took over in August and has ushered in widespread job cuts and a drive to refocus the company on its key markets.</p><p>One portfolio manager told Reuters he did not favor the changes, saying quote, "I don't really get it – why does the old CEO have to be the new Chairman? Don't like it."</p><p>U.S.-listed shares of Novo Nordisk fell 1.7% Tuesday</p></body>

Description: Eli Lilly (LLY) reached $799.57 at the closing of the latest trading day, reflecting a -1.16% change compared to its last close.

Description: The board turmoil represents a breakdown in relations between the company and its controlling shareholder.

Description: The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include the rising diabetes prevalence, advancements in insulin delivery systems, and a surge in personalized diabetes solutions. Rapid acting insulin, essential for managing post-meal blood sugar surges, is favored for its quick efficacy. Innovations such as insulin pens and pumps, coupled with favorable he

Description: Insider company trading doesn't always follow the same script. Here's how to track and make sense of in-house trades

Description: The tides continue to change in Eli Lilly's favor in the GLP-1 space.

Description: By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT With investors perched on the edge of their seats for months, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announces a deal including upfront milestones and partner-funded asset development. On October 18 th Rani and Chugai Pharmaceutical disclosed a collaboration and license agreement that includes a $10 million upfront

Description: These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.

Description: These companies are jockeying for position in a potential $150 billion market opportunity.

Description: These two high-quality stocks can deliver impressive returns in the long run.

Description: The Dow Jones Industrial Average and other key indexes wrapped up the week on a high note after President Donald Trump's latest tariff update Friday eased the worst fears for investors. Dow component American Express shot up, flexing technical strength, while a regional bank's earnings assuaged some lending concerns on the stock market today.

Description: Zions Bancorp trades higher following a drop of 13% in the previous session on bank loan worries, while American Express rises after posting better-than-expected earnings.

Description: Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of weight-loss drugs.

Description: Shares of drugmakers Novo Nordisk and Eli Lilly fell Friday on concerns about pricing pressure after President Trump said the cost of blockbuster diabetes drug Ozempic, which is also used for weight loss, would come down significantly. Novo Nordisk’s American depositary receipts fell 3.1% and Lilly shares were off 2%. Trump said Thursday the out of pocket cost of Ozempic could fall to $150.

Description: Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro.

Description: Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded after a flurry of corporate earnings reports.

Description: The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive revenue streams for Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY). These medications, including NVO’s Ozempic and Wegovy, and LLY’s Mounjaro and Zepbound, mimic hormones to curb appetite and regulate blood sugar. Their popularity exploded in ... Is Trump Going to Kill the GLP-1 Cash Cow?

Description: Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.

Description: President Trump said he would lower the prices of popular weight-loss drugs, pressuring shares of drugmakers Novo Nordisk and Eli Lilly Friday.

Description: The US list price of Ozempic, which Trump called “the fat loss drug,” is roughly $1,000 for a month’s supply. Trump told reporters on Thursday that the cost of the drug, made by Novo, will soon be “much lower.” Lilly sells similar treatments, including Mounjaro and Zepbound.

Description: Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.”

Description: Trump’s comments on Ozempic “signal aggressive posturing” in drug price negotiations, an analyst said

Description: Morning Brief host Allie Canal tracks several of the day's top trending stock tickers, including shares of Eli Lilly (LLY) and Novo Nordisk (NVO) falling after President Trump said he expects to help ease GLP-1 drug prices lower, American Express (AXP) reporting record revenue in its third quarter earnings results, and EssilorLuxottica (EL.PA, ESLOY) stock rising to a record high boosted by the sale of Meta Platforms' (META) AI-powered Ray-Bans glasses. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.

Description: Weight-Loss Drug Stocks Tumble as Trump Vows Massive Price Cuts

Description: Eli Lilly's prescription for growth and sustainability includes a strong drug pipeline, revenue growth and energy investments.

Description: News of the day for Oct. 17, 2025

Description: Eli Lilly said Friday a combination using Verzenio reduced the risk of death by nearly 16% over two years for breast cancer patients.

Description: Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-),

Description: President Donald Trump said the price of the diabetes drug Ozempic will soon be "much lower" and could come down to just $150 a month, pushing shares of Novo Nordisk A/S and Eli Lilly & Co. lower. Sam Fazeli of Bloomberg Intelligence has more.